Testing if Docetaxel or Paclitaxel Causes Less Peripheral Neuropathy in Black Women with Breast Cancer

Bryan P. Schneider, MD

"We recently discovered that patients of African descent have substantially more neuropathy from some chemotherapies. This side effect has the potential to be permanent and impact quality of life. Most importantly it affects cancer outcomes, which is likely due to the inability to tolerate important chemotherapy. EAZ171 will use DNA biomarkers to better predict which patients will get neuropathy and will help to personalize the best therapy for each patient based on her own unique DNA. We are passionate about ending breast cancer disparities for Black women and hope this trial will be one of many to realize that goal."

-Bryan P. Schneider, MD

STUDY TITLE: Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neuropathy in African American Women

TRIAL NUMBER: NCT04001829 or EAZ171

FOCUS: Quality of Life/Supportive Care

WHAT HAPPENS IN THIS STUDY?

This study hopes to improve outcomes for Black women with breast cancer. There are two goals in this study: 1) to determine which women are most at-risk for neuropathy, a painful side effect from chemotherapy that causes tingling, numbness, pain, muscle weakness in hands and feet; 2) to determine which regularly prescribed chemotherapy treatment, docetaxel or paclitaxel, will result in less of a side effect that causes nerve damage, known as peripheral neuropathy, for Black women with breast cancer.

If your treatment team decides chemotherapy with paclitaxel or docetaxel is right for you and you decide to take part in this study:

> You will receive paclitaxel or docetaxel; provide a sample of blood for research; and answer surveys so researchers can learn more about how the side effects of chemotherapy drugs like docetaxel and paclitaxel affect your life. After you finish your study treatment, your doctor will continue to follow you for up to five years and check with you for side effects. Learn more about this study.

ARE YOU ELIGIBLE?

Women must be of African ancestry and must not have received a taxane or platinum-based chemotherapy treatment for cancer.

The status of this study is subject to change. To see the most current information, visit clinicaltrials.gov.

WHY IS IT IMPORTANT FOR BLACK WOMEN TO PARTICIPATE?

Black patients are strikingly under-represented in clinical trials. Research also shows that Black patients have a much higher risk of experiencing side effects from chemotherapy, especially neuropathy. Neuropathy causes doctors to lower or even stop chemotherapy doses in their patients. In turn, breast cancer comes back (recurs) more often in Black patients compared with white patients and creates worse survival rates in Black people. This study is designed to help figure out why Black women experience more neuropathy and which drugs are best at reducing it.

WHO DO I CONTACT ABOUT THIS STUDY?

STUDY LOCATIONS:

This study is offered at multiple sites across the country. See if there is a research site near you or get contact information for a study location.

LEAD TRIAL PI AND TRIAL SPONSOR:

Bryan P. Schneider, MD (PI), ECOG-ACRIN Cancer Research Group

KOMEN CONNECTION

Bryan P. Schneider, MD, the Principal Investigator (PI) of this Komen funded study, is a Komen Scholar from Indiana University Melvin and Bren Simon Cancer Center. Dr. Schneider cares for breast cancer patients as a medical oncologist and has a special interest in new treatments and markers that help predict who will best respond or experience side effects. His work seeks to identify ways to better guide appropriate patient selection for new therapies.

BREAST CANCER CLINICAL TRIAL INFORMATION HELPLINE

Call our clinical trial information helpline at 1-877 GO KOMEN (1-877-465-6636) or email at clinicaltrialinfo@komen.org to talk with a trained specialist. Our caring and trained staff provide support and education about clinical trials to help people gain a better understanding of clinical trials.

Disclaimer

This information is being provided for education purposes only and does not contain all information related to this clinical study. The study status and eligibility criteria may change. If you are interested in learning if this study is right for you, please reach out to the study coordinator or your doctor for more information.

KOMEN.ORG
1-877-GO KOMEN